covid
Buscar en
Cirugía y Cirujanos (English Edition)
Toda la web
Inicio Cirugía y Cirujanos (English Edition) Prevalence of breast cancer sub-types by immunohistochemistry in patients in the...
Información de la revista
Vol. 83. Núm. 3.
Páginas 193-198 (mayo - junio 2015)
Visitas
3161
Vol. 83. Núm. 3.
Páginas 193-198 (mayo - junio 2015)
Original article
Open Access
Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social
Prevalencia de subtipos por inmunohistoquímica del cáncer de mama en pacientes del Hospital General Regional 72, Instituto Mexicano del Seguro Social
Visitas
3161
Gabriel Pérez-Rodríguez
Autor para correspondencia
gabriel.perezr@imss.gob.mx
gabriel640229@hotmail.com

Correspondence to: Coordinador de Programas Médicos de la División de Atención Ginecobstétrica y Perinatal, Instituto Mexicano del Seguro Social, Calle Durango 289, Roma Norte, Cuauhtémoc, C.P. 06700 México, D.F., México. Tel.: +52 5726 1767 / 5726 1700 Ext. 14141.
División de Atención Ginecobstétrica y Perinatal, Dirección de Prestaciones Médicas Instituto Mexicano del Seguro Social, México, D.F., México
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (4)
Table 1. Tumour categorisation by immunohistochemistry in 4 subtypes.
Table 2. Frequency of subtypes by age ranges.
Table 3. Subtypes and risk factors.
Table 4. Subtypes and tumour characteristics.
Mostrar másMostrar menos
Abstract
Background

Breast cancer mortality has increased in women 25 years and over, and since 2006 it has surpassed cervical cancer. Breast cancer is a heterogeneous disease, with several clinical and histological presentations that require a thorough study of all clinical and pathological parameters, including immunohistochemistry to classify it into subtypes, have a better prognosis, provide individualised treatment, increase survival, and reduce mortality.

Objective

To evaluate the prevalence of sub-types of breast cancer and the association with the clinical and histopathological features of the tumour.

Material and methods

An observational, retrospective, cross-sectional and analytical study was conducted on 1380 patients with a diagnosis of breast cancer, and they have been classified by immunohistochemistry into four subtypes: luminal A, triple negative, luminal B and HER2. An analysis was performed on the association with age, risk factors, and the clinical and histopathological features of the tumour.

Results

The mean age of the patients was 53.3±11.4 years. The frequency was luminal A (65%), triple negative (14%), luminal B (12%), and HER2 (9%). The most frequent characteristics were in the 50–59 age range, late menopause, the right side, upper external quadrant, stage II, metastatic lymph nodes, and mastectomy.

Conclusion

The most frequent sub-type was luminal A, and together with the luminal B they have better prognosis compared with the triple negative and HER2.

Keywords:
Breast cancer
Molecular subtypes
Immunohistochemistry
Resumen
Antecedentes

El cáncer de mama ha incrementado la mortalidad en mujeres de 25 años y más, superando al cáncer cervicouterino. Es una enfermedad heterogénea, de presentación clínica e histológica variada con diferentes subtipos, por lo que es indispensable el diagnóstico preciso clínico y anatomopatológico (que incluye la inmunohistoquímica); solo así el tratamiento se individualizará y el pronóstico mejorará y se incrementará la sobrevida, con disminución de la mortalidad.

Objetivo

Analizar la prevalencia de los subtipos del cáncer de mama y su asociación con las características clínicas e histopatológicas del tumor.

Material y métodos

Estudio observacional, retrospectivo, transversal y analítico, realizado en 1,380 pacientes con diagnóstico de cáncer de mama que se clasificaron por inmunohistoquímica en 4 subtipos: luminal A, triple negativo, luminal B y HER2. Se analizó la asociación de las características clínicas e histopatológicas del tumor con la edad y los factores de riesgo.

Resultados

Las pacientes tuvieron edades de 53.3±11.4, la frecuencia de los subtipos fue: luminal A (65%), triple negativo (14%), luminal B (12%) y HER2 (9%): las características más frecuentes fueron: el rango de edad de 50 a 59 años, menopausia tardía, mama derecha, cuadrante superoexterno, la etapa II, los ganglios metastásicos y la mastectomía.

Conclusiones

El subtipo más frecuente fue el luminal A, y junto con el luminal B son los que tienen mejor pronóstico en comparación con el triple negativo y HER2.

Palabras clave:
Cáncer de mama
Subtipos moleculares
Inmunohistoquímica
Texto completo
Background

Breast cancer has become more prevalent in recent decades and is now the most common cancer worldwide. It represents 16% of all types of female cancer, and although it is considered a first-world illness, most deaths are registered in developing countries.1,2 The low survival rates in these countries can mainly be explained by the lack of efficient programmes to detect, diagnose and treat the disease.3 The increase in breast cancer mortality is a public health issue, given that since 2006 it has surpassed cervical cancer.4 Breast cancer is a heterogeneous disease that presents with different clinical and histopathological characteristics at the moment of diagnosis. The prognosis factors are the individual characteristics of the tumour and the patient, and their analysis and assessment are essential to choose the most specific and efficient treatment to increase survival and reduce mortality.5,6 In 2006, Carey et al.7 categorised breast cancer by immunohistochemistry (IHC) in: luminal A (ER+ and/or PR+ and HER2−), luminal B (ER+ and/or PR+ and HER2+), basal-like (ER−, PR−, HER2−, cytokeratin 5/6 positive or HER1+), HER2+/ER− (ER−, PR− and HER2+) and with no categorisation when they tested negative for the five markers (RE, RP, HER2neu, HER1 and cytokeratin 5/6).

This method represents a more feasible alternative since half of breast cancer cases occur in countries where the analysis of prognosis factors must be inexpensive, simple and easy to replicate. Luminal A and B subtypes are the ones with the best prognosis and respond to hormone therapy; HER2 and triple negative have the worst prognosis and are only responsive to chemotherapy.8,9 Several studies concur that luminal A subtype is the most common one.10–12 The current histological categorisation of breast carcinomas does not reflect the heterogeneity of tumours in their biological behaviour, nor does it allow identifying the patients who will have a better response or who will benefit from the different therapies. The clinical and prognostic diversity of breast carcinomas are similar and homogeneous regarding their classic prognosis factors, but express different genes at a molecular level that ascribe them biological and prognostic variability; studying these genes has enabled us to understand the biological behaviour of breast cancer and to personalise prognosis and treatment for patients.13–15 Several studies suggest that with a limited amount of immunohistochemistry markers, breast carcinomas can be categorised into subtypes equivalent to those based on gene expression profiles; the advantage of the immunohistochemistry analysis is that it uses markers that are available at most anatomical pathology services.16–18 This categorisation reveals prognostic differences with statistical importance in the recurrence, survival and mortality of triple negative and HER2 subtypes, compared to luminal A and B subtypes.19–21

The purpose of this study was to analyse the predominance of breast cancer subtypes by immunohistochemistry and to analyse the association between age, risk factors, and clinical and histopathological characteristics of the tumour.

Material and methods

An observational, retrospective, cross-sectional and analytical study conducted for a period of seven years, from 1 January 2007 to 31 December 2013, at the Hospital General Regional 72 of the Instituto Mexicano del Seguro Social, which was a reference hospital for East Mexico, West Mexico and the North Federal District areas for oncology services during that period. The surgical oncology service registered 9.058 first-time consultations, whereas the Hospital General Regional 196 from the same area registered 4787. 1380 patients were included who met the inclusion criteria: having stage I, II and III breast cancer, having being treated with radical curative surgery (quadrantectomy or mastectomy with axillary dissection) and having immunohistochemistry results. Depending on the immunohistochemistry results, they were categorised into four subtypes: luminal A (RE+, RP+, HER2−), triple negative (RE−, RP−, HER2−), luminal B (RE+, RP+, HER2+) and HER2 (RE−, RP−, HER2+). The association between subtypes and clinical and histopathological variables such as age, risk factors, affected side, quadrant, clinical stage, tumour size, type of surgery and metastatic ganglia was analysed.

The descriptive statistics were calculated for the frequency and percentage variables, and square Chi was calculated to analyse the link between variables and subtypes using the SPSS programme, version 20.

Results

There were 1380 patients with breast cancer diagnosis, age range between 30 and 86 years, mean 53.3±11.4, and they were categorised into four subtypes by immunohistochemistry. The frequency was luminal A (65%), triple negative (14%), luminal B (12%) and HER2 (9%) (Table 1).

Table 1.

Tumour categorisation by immunohistochemistry in 4 subtypes.

Type of receptor  Luminal A  Triple negative  Luminal B  HER2 
  n (%)  n (%)  n (%)  n (%) 
  896 (65)  190 (14)  171 (12)  123 (9) 
Oestrogen  (+)  (−)  (+)  (−) 
Progesterone  (+)  (−)  (+)  (−) 
HER2  (−)  (−)  (+)  (+) 

(+): positive; (−): negative.

By grouping patients by age, the highest frequency was observed in the age range 50–59 years (31%); by analysing the association between subtypes and age ranges, the highest frequency was found between luminal A and 80–89 years (3%), luminal B with 40–49 years (37%) and with 60–69 years (26%), and HER2 with 30–39 years (21%) and with 50–59 years (37%) with a significant p. The age range between 70 and 79 was not linked to any subtype, nor was there an association between the triple negative subtype to any age range (Table 2).

Table 2.

Frequency of subtypes by age ranges.

Age range  Luminal ATriple negativeLuminal BHER2TotalValue of p 
  n  n  n  n  n   
  896  65  190  14  171  12  123  1380  100   
30–39  111  12  22  12  15  26  21  174  13  0.01 
40–49  221  25  55  29  64  37  33  27  373  27  0.007 
50–59  289  32  66  35  29  17  45  37  429  31  0.0001 
60–69  181  20  29  15  45  26  12  10  267  19  0.002 
70–79  68  18  18  11  109  0.1 
80–89  26  28  0.01 

Of the risk factors, the most frequent was late menopause (25%), although in the statistical analysis there was no association with any subtype; there was only an association between HER2 subtype with women who had never been pregnant (14%), with a significant p (Table 3).

Table 3.

Subtypes and risk factors.

Risk factor  Luminal ATriple negativeLuminal BHER2TotalValue of p 
  n  n  n  n  n   
  925  68  181  13  153  11  107  1366  100   
Inheritance  130  14  20  11  32  21  18  17  200  15  0.1 
Menarche  140  15  34  19  20  13  16  15  210  15  0.3 
Women who have never been pregnant  97  10  21  12  11  15  14  144  11  0.01 
Oral hormones  162  18  37  20  23  15  10  232  17  0.3 
Late pregnancy  163  18  30  17  22  14  19  18  234  17  0.3 
Late menopause  233  25  39  22  45  29  29  27  346  25  0.4 

The characteristics of the most common tumour were: right side 53%, upper outer quadrant 66%, stage II 69%, mastectomy 71%, T2 size 68% and metastatic ganglia 64%. Association of subtypes with tumour characteristics was found between luminal A with stage I (10%), stage II (70%), T1 size (10%), T2 size (69%) and non-metastatic ganglia (39%); triple negative with upper outer quadrant (79%) and conservative surgery (32%); luminal B with mastectomy (79%); HER2 with stage III (35%), T3 size (37%), mastectomy (79%) and metastatic ganglia (72%), with a significant p; there was no association between sides and subtypes (Table 4).

Table 4.

Subtypes and tumour characteristics.

Tumour characteristics  Luminal ATriple negativeLuminal BHER2TotalValue of p 
  n  n  n  n  n   
  896  65  190  14  171  12  123  1380  100   
Side                      0.69 
Right  485  54  96  51  86  50  65  53  732  53   
Left  411  46  94  49  85  50  58  47  648  47   
Place                      0.0001 
UOQ  582  65  150  79  107  62  69  56  908  66   
UIQ  90  10  11  20  12  10  131   
LOQ  18  36   
LIQ  30  48   
Medial  176  20  19  10  30  17  32  26  257  19   
Stage                      0.001 
88  10  16  13  119   
II  626  70  131  69  119  69  78  63  954  69   
III  182  20  43  23  39  23  43  35  307  22   
Surgery                      0.005 
Conservative  281  31  61  32  36  21  26  21  404  29   
Mastectomy  615  69  129  68  135  79  97  79  976  71   
Size                      0.001 
T12cm  88  10  16  13  119   
T2 >2 and ≤5cm  620  69  131  69  115  67  76  61  942  68   
T3>5cm  188  21  43  23  43  25  45  37  319  23   
Ganglia                      0.005 
Non-metastatic  353  39  62  33  50  29  34  28  499  36   
Metastatic  543  61  128  67  121  71  89  72  881  64   

Medial: Retroareolar; LOQ: lower outer quadrant; LIQ: lower inner quadrant; UOQ: upper outer quadrant; UIQ: upper inner quadrant.

Discussion

In this study, we found a predominance of luminal A subtype (65%), triple negative subtype (14%), luminal B subtype (12%) and HER2 subtype (9%), slightly different to what was reported by Uribe and his team,10 who reported 60%, 29%, 9% and 2% respectively; while Arrechea et al.11 reported 62.5%, 8.4%, 18% and 9.9% and Calderón and his team12 reported 56%, 19%, 8% and 17%. In all the studies, luminal A subtype was the most frequent and exceeded 50%.

An association between subtypes and the patients’ age ranges was found between luminal A subtype and women aged 80–89. This can be explained, since positive hormone receptors are more common in postmenopausal women, as opposed to HER2 subtype, which was associated with age range 30–39, where positive hormone receptors are less common in premenopausal women.

Out of the risk factors, the most common one was late menopause (25%), but it was not associated with any subtype. Only HER2 subtype was associated with women who had never been pregnant.

The tumour characteristics associated with luminal A subtype were stages I and II, T1 and T2 size and non-metastatic ganglia. These characteristics have a better prognosis, as opposed to HER2 subtype, which was associated with stage III, T3 size, metastatic ganglia and mastectomy. These characteristics have a poorer prognosis.19–22

Luminal A and B subtypes represent more than 75% in which hormone therapy is indicated as another form of systemic treatment, although since luminal B subtypes are HER2+ they do not have the same response to hormone therapy as luminal A subtypes. Targeted therapy with trastuzumab monoclonal antibody is indicated for luminal B and HER2 subtypes, while for the triple negative subtype neither hormone therapy nor trastuzumab is indicated, only chemotherapy as systemic treatment.23–25

Information campaigns have been launched in the media to promote self-examination in women over the age of 25, as well as screening mammographies in women over the age of 40, with the purpose of diagnosing them at the early stages when the tumour is smaller than 1cm and can be treated efficiently; there is a survival rate over 95%, so mortality would be reduced. In this study, stage I represented only 9%.

Conclusions

In this study, as in other studies, luminal A subtype is the most common one, over half of the cases; luminal A and B subtypes represent more than 3/4 parts. As for the other subtypes, there are slight differences that could be explained by the type of population under study. Luminal A is the one with the best prognosis, followed by luminal B, then HER2, and lastly triple negative. Out of the risk factors, late menopause was the most common one and it was identified in a quarter of the women. Out of the tumour characteristics, a size that is smaller than 2cm, stage I and non-metastatic ganglia are factors with a better prognosis and are associated with luminal A subtype, as opposed to tumours larger than 5cm, stage III and metastatic ganglia, which are factors with a poorer prognosis and are associated with HER2 subtype.

Conflict of interests

The author declares that there are no conflicts of interest.

References
[1]
G. Aguayo-Alcaraz, L.M. Jiménez-Pérez, A. Celis-de la Rosa, J.L. Canales-Muñoz.
Mortalidad por cáncer de mama. Tendencia y distribución geográfica, 1981–2001.
Rev Med Inst Mex Seguro Soc, 46 (2008), pp. 367-374
[2]
E. De la Vara-Salazar, L. Suárez-López, A. Ángeles-Llerenas, G. Torres-Mejía, E. Lazcano-Ponce.
Tendencias de la mortalidad por cáncer de mama en México, 1980–2009.
Salud Publica Mex, 53 (2011), pp. 385-393
[3]
E. De la Vara-Salazar, L.S. Palacio-Mejía, C. Oropeza, M. Hernández, E. Lazcano-Ponce.
Perfil epidemiológico de la mortalidad en el sureste de México, 1980–2008.
[4]
F.M. Knaul, G. Nigenda, R. Lozano, H. Arreola-Ornelas, A. Langer, J. Frenk.
Cáncer de mama en México: una prioridad apremiante.
Salud Publica Mex, 51 (2009), pp. S335-S344
[5]
V.M. Pérez Sánchez, T.A. Vela Chávez, A. Mora Tiscareño.
Diagnóstico histopatológico y factores pronóstico en cáncer infiltrante de glándula mamaria.
Cancerología, 3 (2008), pp. 7-17
[6]
R.I. Álvarez Goyanes, X. Escobar Pérez, R. Camacho Rodríguez, M. Orozco López, S. Franco Odio, L. Llanes Fernández, et al.
Receptores hormonales y otros factores pronósticos en cáncer de mama en Cuba.
Cancerología, 3 (2008), pp. 19-27
[7]
L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, et al.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
J Am Med Assoc, 295 (2006), pp. 2492-2502
[8]
E.J. Zepeda-Castilla, E. Recinos-Money, M. Cuéllar-Hubbe, C.D. Robles-Vidal, E. Maafs-Molina.
Clasificación molecular del cáncer de mama.
Cir Ciruj, 76 (2008), pp. 87-93
[9]
M.A. Munirah, M.A. Siti-Aishah, M.Z. Reena, N.A. Sharifah, M. Rohaizak, A. Norlia, et al.
Identification of different subtypes of breast cancer using tissue microarray.
Rom J Morphol Embryol, 52 (2011), pp. 669-677
[10]
J.R. Uribe, C.A. Hernández, F. Menolascino, J.E. Rodríguez, L.M. Istúriz, M.E. Márquez, et al.
Clasificación molecular del cáncer de mama y su correlación clínica.
Rev Venez Oncol, 22 (2010), pp. 109-116
[11]
M. Arrechea Irigoyen, F. Vicente García, A. Córdoba Iturriagagoitia, B. Ibáñez Beroiz, M. Santamaría Martínez, F. Guillén Grima.
Subtipos moleculares del cáncer de mama: implicaciones pronósticas y características clínicas e inmunohistoquímicas.
An Sist Sanit Navar, 34 (2011), pp. 219-233
[12]
A.L. Calderón-Garcidueñas, G. Martínez-Reyes, A.I. Gallardo-Gómez, A. Rojas-Martínez, R.M. Cerda-Flores.
Triple marker immunohistochemestry analysis in breast cancer Mexican patients.
Patología, 50 (2012), pp. 72-79
[13]
C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, et al.
Molecular portraits of human breast tumors.
Nature, 406 (2000), pp. 747-752
[14]
T. Sørlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, A. Nobel, et al.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Proc Natl Acad Sci USA, 100 (2003), pp. 8418-8423
[15]
J.A. Foekens, D. Atkins, Y. Zhang, F.C.G.J. Sweep, N. Harbeck, A. Paradiso, et al.
Multicenter Validation of a Gene Expression-Based Prognostic Signature in Lymph Node-Negative Primary Breast Cancer.
J Clin Oncol, 24 (2006), pp. 1665-1671
[16]
T.O. Nielsen, F.D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, et al.
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Clin Cancer Res, 10 (2004), pp. 5367-5374
[17]
C.A. Livasy, G. Karaca, R. Nanda, M.S. Tretiakova, O.I. Olopade, D.T. Moore, et al.
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Mod Pathol, 19 (2006), pp. 264-271
[18]
M.L. Burness, T.A. Grushko, O.I. Olopade.
Epidermal growth factor receptor in triple-negative and basal-like breast cancer: Promising clinical target or only a marker?.
[19]
A. Spitale, P. Mazzola, D. Soldini, L. Mazzucchelli, A. Bordoni.
Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland.
Ann Oncol, 20 (2009), pp. 628-635
[20]
K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, V. Caggiano.
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry.
Cancer, 109 (2007), pp. 1721-1728
[21]
X.R. Yang, M.E. Sherman, D.L. Rimm, J. Lissowska, L.A. Brinton, B. Peplonska, et al.
Differences in risk factors for breast cancer molecular subtypes in a population-based study.
Cancer Epidemiol Biomarkers Prev, 16 (2007), pp. 439-443
[22]
A.A. Onitilo, J.M. Engel, R.T. Greenlee, B.N. Mukesh.
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Clin Med Res, 7 (2009), pp. 4-13
[23]
K.D. Voduc, M.C. Cheang, S. Tyldesley, K. Gelmon, T.O. Nielsen, H. Kennecke.
Breast cancer subtypes and the risk of local and regional relapse.
J Clin Oncol, 28 (2010), pp. 1684-1691
[24]
C.S. Vallejos, H.L. Gómez, W.R. Cruz, J.A. Pinto, R.R. Dyer, R. Velarde, et al.
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a Peruvian Hospital database.
Clin Breast Cancer, 10 (2010), pp. 294-300
[25]
K.M. O’Brien, S.R. Cole, C.K. Tse, C.M. Perou, L.A. Carey, W.D. Foulkes, et al.
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
Clin Cancer Res, 16 (2010), pp. 6100-6110

Please cite this article as: Pérez-Rodríguez G. Prevalencia de subtipos por inmunohistoquímica del cáncer de mama en pacientes del Hospital General Regional 72, Instituto Mexicano del Seguro Social. Cir Cir. 2015;83:193–8.

Copyright © 2015. Academia Mexicana de Cirugía A.C.
Descargar PDF
Opciones de artículo